Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody

Open access
Park, Jeong A, Espinosa-Cotton, Madelyn, Guo, Hong-fen, Monette, Sebastien, Cheung, Nai-Kong V · 2023 · Journal for ImmunoTherapy of Cancer

Abstract

Background: Success of T cell immunotherapy hinges on the tumor microenvironment (TME), and abnormal tumor vasculature is a hallmark of most solid tumors and associated with immune evasion. The efficacy of T cell engaging bispecific antibody (BsAb) treatment relies on the successful trafficking and cytolytic activity of T cells in solid tumors. Normalization of tumor vasculature using vascular endothelial growth factor (VEGF) blockades could improve efficacy of BsAb-based T cell immunotherapy. Methods: Anti-human VEGF (bevacizumab, BVZ) or anti-mouse VEGFR2 antibody (DC101) was used as VEGF blockade, and ex vivo armed T cells (EATs) carrying anti-GD2, anti-HER2, or anti-glypican3 (GPC3) IgG-(L)-scFv platformed BsAb were used. BsAb-driven intratumoral T cell infiltration and in vivo antitumor response were evaluated using cancer cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) carried out in BALB-Rag2 -/-IL-2R-γc-KO (BRG) mice. VEGF expression on human cancer cell lines was analyzed by flow cytometry, and VEGF levels in mouse serum were measured using VEGF Quantikine ELISA Kit. Tumor infiltrating lymphocytes (TILs) were evaluated using flow cytometry and by bioluminescence; both TILs and tumor vasculature were studied using immunohistochemistry. Results: VEGF expression on cancer cell lines increased with seeding density in vitro. BVZ significantly reduced serum VEGF levels in mice. BVZ or DC101 increased high endothelial venules (HEVs) in the TME and substantially enhanced (2.1–8.1 fold) BsAb-driven T cell infiltration into neuroblastoma and osteosarcoma xenografts, which was preferential for CD8(+) TILs versus CD4(+) TILs, leading to superior antitumor effects in multiple CDX and PDX tumor models without added toxicities. Conclusions: VEGF blockade using specific antibodies against VEGF or VEGFR2 increased HEVs in the TME and cytotoxic CD8(+) TILs, significantly improving the therapeutic efficacy of EAT strategies in preclinical models, supporting the clinical investigation of VEGF blockades to further enhance BsAb-based T cell immunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2023-006680

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 VEGF blockade enhances BsAb-driven T cell trafficking and persistence in tumors. (A) Luciferase transduced T cells armed ex vivo with anti-HER2 BsAb (Luc(+) HER2-EATs) were administered with BVZ or DC101 to mice bearing HER2(+) HGSOC1 osteosarcoma PDXs, and the bioluminescence of T cells in tumors was monitored over time and quantified as a bioluminescence intensity (BLI, photons/sec). (B) Luciferase transduced T cells armed ex vivo with anti-GD2 BsAb (Luc(+) GD2-EATs) were administered with BVZ or DC101 to treat GD2(+) neuroblastoma PDXs, and the bioluminescence of T cells in tumors was analyzed.*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BsAb, bispecific antibody; BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.
Figure 1 VEGF blockade enhances BsAb-driven T cell trafficking and persistence in tumors. (A) Luciferase transduced T cells armed ex vivo with anti-HER2 BsAb (Luc(+) HER2-EATs) were administered with BVZ or DC101 to mice bearing HER2(+) HGSOC1 osteosarcoma PDXs, and the bioluminescence of T cells in tumors was monitored over time and quantified as a bioluminescence intensity (BLI, photons/sec). (B) Luciferase transduced T cells armed ex vivo with anti-GD2 BsAb (Luc(+) GD2-EATs) were administered with BVZ or DC101 to treat GD2(+) neuroblastoma PDXs, and the bioluminescence of T cells in tumors was analyzed.*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BsAb, bispecific antibody; BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.CC BY-NC · PubMed Central
Figure 2 VEGF blockade enhances GD2-EAT infiltration into neuroblastoma and particularly, increased intratumoral CD8(+) T cells. (A) Neuroblastoma PDXs were treated with a combination of GD2-EATs and anti-VEGF (BVZ) or VEGFR2 antibody (DC101). Tumors were harvested on day 10 post-EAT treatment and analyzed by flow cytometry. (B) Immunohistochemical staining (IHC) of neuroblastoma PDXs. Tumors were harvested on day 10 post-EAT treatment and stained with anti-human CD3, anti-human CD4, and anti-human CD8 antibody. (C) Intratumoral CD3, CD4, and CD8 T cells were quantified by positive pixel count analyses and compared among groups. G1, no treatment; G2, unarmed T cells; G3, GD2-EATs; G4, GD2-EATs plus BVZ; G5, GD2-EATs plus DC101. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.
Figure 2 VEGF blockade enhances GD2-EAT infiltration into neuroblastoma and particularly, increased intratumoral CD8(+) T cells. (A) Neuroblastoma PDXs were treated with a combination of GD2-EATs and anti-VEGF (BVZ) or VEGFR2 antibody (DC101). Tumors were harvested on day 10 post-EAT treatment and analyzed by flow cytometry. (B) Immunohistochemical staining (IHC) of neuroblastoma PDXs. Tumors were harvested on day 10 post-EAT treatment and stained with anti-human CD3, anti-human CD4, and anti-human CD8 antibody. (C) Intratumoral CD3, CD4, and CD8 T cells were quantified by positive pixel count analyses and compared among groups. G1, no treatment; G2, unarmed T cells; G3, GD2-EATs; G4, GD2-EATs plus BVZ; G5, GD2-EATs plus DC101. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.CC BY-NC · PubMed Central
Figure 3 The effect of VEGF blockade on tumor microvasculature. (A) Neuroblastoma PDXs were harvested on day 10 post-EAT treatment, and intratumoral blood vessels were stained using anti-mouse CD31 antibody. CD31 positive cells were quantified with positive pixel count analysis. (B) Combinations of GD2-EATs and anti-VEGF (BVZ) (G4) or anti-VEGFR2 antibody (DC101) (G5) induced high endothelial venules (HEVs) in tumors. (C) Representative image of HEVs in a tumor from G4 (GD2-EATs+BVZ), positively stained with anti-peripheral node addressin (PNA)/MECA79 antibody which specifically stain HEVs and no other types of blood vessels. (D) Double immunofluorescence (IF) staining of PNA/MECA79 and human CD3 was performed in tumors from G4, displaying HEVs and T cell distribution around them. G1, no treatment; G2, unarmed T cells; G3, GD2-EATs; G4, GD2-EATs plus BVZ; G5, GD2-EATs plus DC101. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.
Figure 3 The effect of VEGF blockade on tumor microvasculature. (A) Neuroblastoma PDXs were harvested on day 10 post-EAT treatment, and intratumoral blood vessels were stained using anti-mouse CD31 antibody. CD31 positive cells were quantified with positive pixel count analysis. (B) Combinations of GD2-EATs and anti-VEGF (BVZ) (G4) or anti-VEGFR2 antibody (DC101) (G5) induced high endothelial venules (HEVs) in tumors. (C) Representative image of HEVs in a tumor from G4 (GD2-EATs+BVZ), positively stained with anti-peripheral node addressin (PNA)/MECA79 antibody which specifically stain HEVs and no other types of blood vessels. (D) Double immunofluorescence (IF) staining of PNA/MECA79 and human CD3 was performed in tumors from G4, displaying HEVs and T cell distribution around them. G1, no treatment; G2, unarmed T cells; G3, GD2-EATs; G4, GD2-EATs plus BVZ; G5, GD2-EATs plus DC101. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.CC BY-NC · PubMed Central
Figure 4 In vivo antitumor effect of combination therapies of GD2-EATs and VEGF blockades against osteosarcomas. (A) 143B osteosarcoma CDXs were treated by GD2-EATs with or without VEGF blockades, and in vivo tumor suppressing effects and overall survival were compared among groups. (B) TEOSC1 osteosarcoma PDXs were treated by GD2-EATs with or without VEGF blockade. Tumor growth curves and overall survival were plotted and compared among groups. G1, no treatment; G2, unarmed T cells; G3, GD2-EATs; G4, GD2-EATs plus BVZ; G5, GD2-EATs plus DC101. (C) H&E staining of tumors harvested on day 180 post-treatment. Tumors in G4 and G5 (combination therapy of GD2-EATs with VEGF blockade) showed extramedullary hematopoiesis and bone mineralization without visible tumor cells, which contrasted with those in G3 (GD2-EATs alone) showing viable chondroid differentiating osteosarcoma. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.
Figure 4 In vivo antitumor effect of combination therapies of GD2-EATs and VEGF blockades against osteosarcomas. (A) 143B osteosarcoma CDXs were treated by GD2-EATs with or without VEGF blockades, and in vivo tumor suppressing effects and overall survival were compared among groups. (B) TEOSC1 osteosarcoma PDXs were treated by GD2-EATs with or without VEGF blockade. Tumor growth curves and overall survival were plotted and compared among groups. G1, no treatment; G2, unarmed T cells; G3, GD2-EATs; G4, GD2-EATs plus BVZ; G5, GD2-EATs plus DC101. (C) H&E staining of tumors harvested on day 180 post-treatment. Tumors in G4 and G5 (combination therapy of GD2-EATs with VEGF blockade) showed extramedullary hematopoiesis and bone mineralization without visible tumor cells, which contrasted with those in G3 (GD2-EATs alone) showing viable chondroid differentiating osteosarcoma. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.CC BY-NC · PubMed Central
Figure 5 In vivo antitumor effect of combination therapies of EATs and VEGF blockade. (A) Synergistic antitumor effects between GD2-EATs and VEGF blockades were tested in a neuroblastoma PDX model. Tumor growth, mouse weight, and overall survival curves were plotted and compared among groups. G1, no treatment; G2, unarmed T cells; G3, GD2-EATs; G4, GD2-EATs plus BVZ; G5, GD2-EATs plus DC101. (B) In vivo antitumor effects of GPC3-EATs (T cells armed ex vivo with anti-GPC3 BsAb) and VEGF blockade combination were tested using HepG2 hepatoblastoma CDXs. Tumor growth, changes in body weight, and overall survival were monitored and analyzed. G1, unarmed T cells; G2, GPC3-EATs; G3, GPC3-EATs plus BVZ; G4, GPC3-EATs plus DC101. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BsAb, bispecific antibody; BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.
Figure 5 In vivo antitumor effect of combination therapies of EATs and VEGF blockade. (A) Synergistic antitumor effects between GD2-EATs and VEGF blockades were tested in a neuroblastoma PDX model. Tumor growth, mouse weight, and overall survival curves were plotted and compared among groups. G1, no treatment; G2, unarmed T cells; G3, GD2-EATs; G4, GD2-EATs plus BVZ; G5, GD2-EATs plus DC101. (B) In vivo antitumor effects of GPC3-EATs (T cells armed ex vivo with anti-GPC3 BsAb) and VEGF blockade combination were tested using HepG2 hepatoblastoma CDXs. Tumor growth, changes in body weight, and overall survival were monitored and analyzed. G1, unarmed T cells; G2, GPC3-EATs; G3, GPC3-EATs plus BVZ; G4, GPC3-EATs plus DC101. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. BsAb, bispecific antibody; BVZ, bevacizumab; EATs, T cells armed ex vivo with BsAb; PDXs, patient-derived xenografts; VEGF, vascular endothelial growth factor.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 46

Metadata

Authors
Park, J. A., Espinosa-Cotton, M., Guo, H.-F., Monette, S., & Cheung, N.-K. V.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Corresponding author
Cheung, Nai-Kong V
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2023-03
Volume
11
Issue
3
Pages
e006680
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4361295500
Cited by
46
References
59
Citations by year
2026: 10 · 2025: 17 · 2024: 14 · 2023: 5
FWCI
4.09
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Kids Walk for Kids with Cancer (N/A)
  • NCI Cancer Center Support Grant (P30 CA008748)
  • Korea Health Technology R&D Project (HI12C1488)
  • Enid A. Haupt Endowed Chair (N/A)
  • Robert Steel Foundation (N/A)
  • Inha University Research Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tumor vasculature normalization, VEGF inhibition, T-cell bispecific antibodies, ex vivo T cell engineering, tumor microenvironment, VEGFR2, bevacizumab, DC101, high endothelial venules, T cell infiltration, tumor-infiltrating lymphocytes, CD8+ T cells, neuroblastoma, osteosarcoma, GD2, HER2
MeSH terms
Animals, Humans, Immunotherapy, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Antibodies, Bispecific, Vascular Endothelial Growth Factor A, Mice, Glypicans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. https://app.cochat.ai/papers/10.1136/jitc-2023-006680
The paper
Park, J. A., Espinosa-Cotton, M., Guo, H.-F., Monette, S., & Cheung, N.-K. V. (2023). Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-006680

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.